Metanoi Therapeutics

Atlanta, United States Founded: 2019 • Age: 7 yrs
Develops patented oral treatments targeting cancer cells in humans and veterinary markets.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors 11 Brand Intelligence

About Metanoi Therapeutics

Metanoi Therapeutics is a company based in Atlanta (United States) founded in 2019. It operates as a B2B and Product Sales. Metanoi Therapeutics offers products and services including VET001 and MET001. Metanoi Therapeutics operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.

  • Headquarter Atlanta, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Metanoi Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Metanoi Therapeutics

Metanoi Therapeutics offers a comprehensive portfolio of products and services, including VET001 and MET001.

Product name locked
Category locked
Primary

Oral therapy for treating cancer in dogs through nutrient depletion.

Product name locked
Category locked
Locked

Oral therapy targeting human cancers by inducing cell death.

Funding Insights of Metanoi Therapeutics

Premium access

Detailed funding history for Metanoi Therapeutics

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Metanoi Therapeutics

Investments
Premium access

Investment portfolio details for Metanoi Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Metanoi Therapeutics

Premium access

Detailed financials for Metanoi Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Metanoi Therapeutics Comparisons

Metanoi Therapeutics Primary company
Description
Develops patented oral treatments targeting cancer cells in ...
Location
Atlanta, United States
Founded Year
2019
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Metanoi Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Metanoi Therapeutics

Metanoi Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Shattuck Labs, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
T cell-based treatments for immunological and oncological disorders are developed.
Locked Locked Locked
CAR-T and TIL immunotherapies for solid tumors are developed.
Locked Locked Locked
Antibody drugs for cancer treatment are developed.
Locked Locked Locked
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
Locked Locked Locked
An immunotherapy platform for oncology and other diseases is developed.
Locked Locked Locked
Viral immunotherapies are developed for cancer treatment.
Premium access

Detailed competitors of Metanoi Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Metanoi Therapeutics

Premium access

Complete news archive for Metanoi Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Metanoi Therapeutics

Metanoi Therapeutics was founded in 2019.

Metanoi Therapeutics is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.

Metanoi Therapeutics creates innovative, non-toxic oral therapies that selectively deplete nutrients in cancer cells, leading to their destruction while sparing healthy tissue. The company focuses on oncology for both humans and animals, with products like VET001 for veterinary use and MET001 for human trials. They conduct preclinical studies and seek FDA approvals to enter markets, providing complementary treatments alongside standard therapies.

Metanoi Therapeutics's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.

Metanoi Therapeutics offers VET001 and MET001.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available